This article is
- freely available
Clinical Toxicities of Histone Deacetylase Inhibitors
TRI, Inc., 6500 Rock Spring Dr, Bethesda, MD 20817, USA
Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
* Author to whom correspondence should be addressed.
Received: 23 June 2010; in revised form: 18 August 2010 / Accepted: 19 August 2010 / Published: 26 August 2010
Abstract: The HDAC inhibitors are a new family of antineoplastic agents. Since the entry of these agents into our therapeutic armamentarium, there has been increasing interest in their use. Although this family comprises chemical compounds from unrelated chemical classes that have different HDAC isoform specificities, they surprisingly have very similar toxicity profiles. In contrast, the observed toxicity profile is somewhat different from that of traditional cytotoxic chemotherapeutic agents and from other epigenetic agents. While some of the side effects may be familiar to the oncologist, others are less commonly seen. As some patients remain on therapy for a prolonged period of time, the long-term sequelae need to be characterized. In addition, since preclinical models suggest promising activity when used in combination with other antineoplastic agents, combination trials are being pursued. It will thus be important to distinguish the relative toxicity attributed to these agents and be alert to the exacerbation of toxicities observed in single agent studies. Notably, few of the agents in this class have completed phase 2 testing. Consequently, more clinical experience is needed to determine the relative frequency of the observed side effects, and to identify and develop approaches to mitigate potential clinical sequelae.
Keywords: histone deacetylase inhibitors; HDAC; toxicities; chemotherapy; clinical trial; HDI
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Subramanian, S.; Bates, S.E.; Wright, J.J.; Espinoza-Delgado, I.; Piekarz, R.L. Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals 2010, 3, 2751-2767.
Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals. 2010; 3(9):2751-2767.
Subramanian, Srividya; Bates, Susan E.; Wright, John J.; Espinoza-Delgado, Igor; Piekarz, Richard L. 2010. "Clinical Toxicities of Histone Deacetylase Inhibitors." Pharmaceuticals 3, no. 9: 2751-2767.